Use of cyclosporine in lung transplantation

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S318-S322

  Parekh, K ^a   Trulock, E ^a   Patterson, G A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALCOHOL; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZATHIOPRINE; BASILIXIMAB; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; COLCHICINE; CYCLOPHILIN; CYCLOSPORIN A; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPENEM; INTERLEUKIN 2; ITRACONAZOLE; KETOCONAZOLE; METHYLPREDNISOLONE; METOCLOPRAMIDE; PREDNISONE; PYRROLE DERIVATIVE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VERAPAMIL;

AKINETIC MUTISM; ANOREXIA; ANXIETY DISORDER; APRAXIA; BRONCHITIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMA; DIARRHEA; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GENETIC TRANSCRIPTION; GINGIVA HYPERPLASIA; GRAFT REJECTION; HEADACHE; HEMOLYTIC UREMIC SYNDROME; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; LEUKOENCEPHALOPATHY; LEUKOPENIA; LUNG TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEIZURE; SKIN TUMOR; SLEEP DISORDER; SPEECH APRAXIA; SPEECH DISORDER; SURVIVAL; T LYMPHOCYTE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREMOR; VISUAL DISORDER; VOMITING;

EID: 1642352675     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.056     Document Type: Article

References (27)

1. Grover F.L., et al. The past, present, and future of lung transplantation. Am J Surg. 173:1997;523.
2. Derom F., et al. Ten-month survival after lung homotransplantation in man. J Thorac Cardiovasc Surg. 61:1971;835.
3. Lima O., et al. Effects of methylprednisolone and azathioprine on bronchial healing following lung autotransplantation. J Thorac Cardiovasc Surg. 82:1981;211.
4. Goldberg M., et al. A comparison between cyclosporin A and methylprednisolone plus azathioprine on bronchial healing following canine lung autotransplantation. J Thorac Cardiovasc Surg. 85:1983;821.
5. Unilateral lung transplantation for pulmonary fibrosis. Toronto Lung Transplant Group. N Engl J Med 314:1140, 1986.
6. Wiederrecht G., et al. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci. 696:1993;9.
7. Kahan B.D. Cyclosporine. N Engl J Med. 321:1989;1725.
8. Schreiber S.L., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunol Today. 13:1992;136.
9. 2+ signals and immunosuppression. Nature. 383:1996;837.
10. Keenan R.J., et al. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg. 113:1997;335.
11. Iacono A.T., et al. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med. 153:1996;1451.
12. Husain A.N., et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 159:1999;829.
13. Hopkins P.M., et al. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant. 21:2002;1062.
14. Estenne M., et al. Bronchiolitis obliterans syndrome 2001 an update of the diagnostic criteria. J Heart Lung Transplant. 21:2002;297.
15. Trulock E.P., et al. The Registry of the International Society for Heart and Lung Transplantation Twentieth Official adult lung and heart-lung transplant report - 2003. J Heart Lung Transplant. 22:2003;625.
16. Kesten S., et al. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome. J Heart Lung Transplant. 16:1997;905.
17. Speich R., et al. Salvage therapy with mycophenolate mofetil for lung transplant bronchiolitis obliterans importance of dosage. Transplantation. 64:1997;533.
18. Ojo A.O., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 349:2003;931.
19. Ramalingam P., et al. Posttransplant lymphoproliferative disorders in lung transplant patients the Cleveland Clinic experience. Mod Pathol. 15:2002;647.
20. Armitage J.M., et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant. 10:1991;877.
21. Montone K.T., et al. Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery. 119:1996;544.
22. Paranjothi S., et al. Lymphoproliferative disease after lung transplantation comparison of presentation and outcome of early and late cases. J Heart Lung Transplant. 20:2001;1054.
23. Keenan R.J., et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg. 60:1995;580.
24. McCurry K., Zaldonis D., Keenan R. Long term follow-up of a prospective randomized trial of tacrolimus versus cyclosporine in human lung transplantation. Am J Transplant. 2:(suppl 3):2002;159.
25. Zuckermann A., et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg. 125:2003;891.
26. Reichenspurner H., et al. Optimization of the immunosuppressive protocol after lung transplantation. Transplantation. 68:1999;67.
27. Horning N.R., et al. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant. 17:1998;761.